Find Reports

Select Report Type

Reimbursement Review

Displaying 576 - 600 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Ilaris	Canakinumab	cdr_SR0463_Ilaris.pdf SR0463_Ilaris_sJIA_CL_Report.pdf SR0463_Ilaris_sJIA_PE_Report.pdf SR0463_complete_Ilaris_sJIA_June_21_16_e.pdf SR0463_Ilaris_SJIA_PI_Submissions.pdf	Systemic Juvenile Idiopathic Arthritis	Reimburse with clinical criteria and/or conditions	Complete	Dec 23, 2015	Jun 17, 2016	SR0463-000
Trulicity	dulaglutide	Recommandation et motifs : Rapport mise à jour Submission Status Report Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Diabetes mellitus, Type 2	Reimburse with clinical criteria and/or conditions	Complete	Dec 22, 2015	Jun 16, 2016	SR0462-000
Nucala	Mepolizumab	cdr_SR0461_Nucala.pdf SR0461_Nucala_CL_Report_e.pdf SR0461_Nucala_PE_Report_e.pdf SR0461_complete_Nucala_June-20-16_e.pdf SR0461_Nucala_PI_Submissions.pdf	Asthma, severe eosinophilic	Reimburse with clinical criteria and/or conditions	Complete	Dec 18, 2015	Jun 16, 2016	SR0461-000
Opdivo	Nivolumab	pcodr_provfund_nivolumab_opdivo_nsclc.pdf nivolumab_opdivo_nsclc_fn_rec.pdf nivolumab_opdivo_nsclc_fn_cgr.pdf nivolumab_opdivo_nsclc_fn_egr.pdf nivolumab_opdivo_nsclc_in_rec.pdf nivolumab_opdivo_nsclc_pagfdk.pdf nivolumab_opdivo_nsclc_fdk_bms.pdf nivolumab_opdivo_nsclc_coi_lcc.pdf	Metastatic non small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 29, 2015	Jun 3, 2016	PC0069-000
Vimizim	Elosulfase alfa	SR0456 Vimizim Resubmission.pdf SR0456_complete_Vimizim_May-26_16.pdf SR0456_Vimizim_Resubmission_CL_Report.pdf SR0456_Vimizim_Resubmission_PE_Report.pdf SR0456_Vimizim_Resubmission_PI_Submissions_Consolidated_validated.pdf	Mucopolysaccharidosis IVA (Morquio A syndrome)	Reimburse with clinical criteria and/or conditions	Complete	Nov 10, 2015	May 20, 2016	SR0456-000
Prolia	Denosumab	cdr_SF0453_Prolia.pdf SF0453_complete_RFA-Prolia_May-25-16_e.pdf SF0453_Prolia_RfA_Review_Report.pdf SF0453 Prolia_PI_Submissions.pdf	Osteoporosis	Reimburse with clinical criteria and/or conditions	Complete	Oct 26, 2015	May 20, 2016	SF0453-000
Zepatier	Elbasvir/grazoprevir	cdr_SR0454_grazoprevir_elbasvir.pdf SR0454_complete_Zepatier_May_25-16.pdf SR0454_Zepatier_CL_Report.pdf SR0454_Zepatier_PE_Report.pdf SR0454_grazoprevir+elbasvir_PI_Submissions_Consolidated_validated.pdf	Hepatitis C, chronic	Reimburse with clinical criteria and/or conditions	Complete	Oct 27, 2015	May 19, 2016	SR0454-000
Humira	Adalimumab	SR0455 Humira HS.pdf SR0455_complete_Humira-HS_May-24-16_e.pdf SR0455_HumiraHS_CL_Report.pdf SR0455_HumiraHS_PE_Report.pdf SR0455 Humira HS - _PI_Submissions_Consolidated_validated.pdf	Hidradenitis suppurativa	Reimburse with clinical criteria and/or conditions	Complete	Nov 3, 2015	May 19, 2016	SR0455-000
Holkira Pak	ombitasvir/paritaprevir/ritonavir and dasabuvir	cdr_SF0466_Holkira_Pak.pdf SF0466_complete_Holkira_Pak_May-25-16.pdf SF0466_HolkiraPak_RfA_Review_Report.pdf SF0466_HolkiraPak_RfA_PI_Submissions.pdf	Hepatitis C, chronic	Reimburse with clinical criteria and/or conditions	Complete	Jan 6, 2016	May 19, 2016	SF0466-000
Daklinza	daclatasvir	cdr_SF0467_Daklinza.pdf SF0467_complete_Daklinza_May_25-16.pdf SF0467_Daklinza_RfA_Review_Report.pdf SF0467_Daklinza_RfA_PI_Submissions.pdf	Hepatitis C, Chronic	Reimburse with clinical criteria and/or conditions	Complete	Jan 6, 2016	May 19, 2016	SF0467-000
Fycompa	Perampanel	SR0458 Fycompa PGTCS .pdf SR0458_complete_Fycompa_May-20-16_e.pdf SR0458_Fycompa_PGTCS_CL_Report.pdf SR0458_Fycompa_PE.pdf SR0458_Fycompa_PI_Submissions_Consolidated_validated.pdf	Epilepsy, primary generalized tonic-clonic seizures	Reimburse with clinical criteria and/or conditions	Complete	Nov 24, 2015	May 18, 2016	SR0458-000
Harvoni	ledipasvir, sofosbuvir	SF0465 Harvoni.pdf SF0465_complete_Harvoni RFA_May_19-16.pdf SF0465_Harvoni_Hep_C_RfA_PI_Submissions.pdf SF0465_Harvoni_RfA_Review_Report.pdf	Hepatitis C, chronic	Reimburse with clinical criteria and/or conditions	Complete	Jan 6, 2016	May 18, 2016	SF0465-000
Sovaldi	sofosbuvir	cdr_SF0464_Sovaldi.pdf SF0464_complete_Sovaldi-May_19_16.pdf SF0464_Sovaldi_RfA_Review_Report.pdf SF0464_Sovaldi_RFA_PI_Submissions.pdf	Hepatitis C, chronic	Reimburse with clinical criteria and/or conditions	Complete	Jan 6, 2016	May 18, 2016	SF0464-000
Xolair	Omalizumab (Drug Plan Submission)	cdr_SR0457_Xolair_Resub.pdf SR0457_complete_Xolair_Resub-May_19_16.pdf SR0457_Xolair_Resub_PI_Submissions.pdf SR0457_Xolair_Resubmission_CL_Report_e.pdf SR0457_Xolair_Resubmission_PE_Report_e.pdf	Asthma, severe persistent	Reimburse with clinical criteria and/or conditions	Complete	Nov 18, 2015	May 18, 2016	SR0457-000
Avastin	Bevacizumab	pcodr-provfund_bevacizumab_avastin_proc.pdf pcodr_bevacizumab_avastin_proc_fn_rec.pdf pcodr_bevacizumab_avastin_proc_fn_egr.pdf pcodr_bevacizumab_avastin_proc_fn_cgr.pdf pcodr_bevacizumab_avastin_proc-in_rec.pdf pcodr_bevacizumab_avastin_proc_pagfdk.pdf pcodr_bevacizumab_avastin_proc_fdk_roche.pdf pcodr_bevacizumab_avastin_proc_ptfdk_occ.pdf pcodr_bevacizumab_avastin_proc_coi_occ.pdf	Platinum Resistant Ovarian Cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 29, 2015	May 5, 2016	PC0066-000
Forxiga	Dapagliflozin	cdr_SR0445_Forxiga.pdf SR0445_complete_Forxiga-May_2_16-e.pdf SR0445_Forxiga_CL_Report.pdf SR0445_Forxiga_PE_Report.pdf	Diabetes mellitus, type 2	Do not list	Complete	Sep 4, 2015	Apr 27, 2016	SR0445-000
Pheburane	Sodium phenylbutyrate	SR0452 Pheburane.pdf SR0452_complete_Pheburane-Apr-25_16-e.pdf SR0452_Pheburane_CL_Report.pdf SR0452_Pheburane_PE_Report.pdf	Urea cycle disorders	List	Complete	Oct 20, 2015	Apr 15, 2016	SR0452-000
Humira	Adalimumab	cdr_SR0450_Humira.pdf SR0450_complete_Humira-Apr-19-16_e.pdf SR0450_Humira_UC_CL_Report.pdf SR0450_Humira_UC_PE_Report.pdf SR0450_Humira_UC_PI_Submissions.pdf	Ulcerative colitis	Do not list at the submitted price	Complete	Sep 25, 2015	Apr 15, 2016	SR0450-000
Basaglar	Insulin glargine	cdr_SE0451_Basaglar.pdf SE0451_complete_Basaglar-Apr_19-16-e.pdf SE0451_Basaglar_PI_Submissions.pdf SE0451_Basaglar_SEB_Report.pdf	Diabetes mellitus, type 1; diabetes mellitus, type 2	List with clinical criteria and/or conditions	Complete	Oct 5, 2015	Apr 14, 2016	SE0451-000
Blincyto	Blinatumomab	pcodr_profund_blinatumomab_blincyto_all.pdf blinatumomab_blincyto_all_fn_rec.pdf blinatumomab_blincyto_all_fn_cgr.pdf blinatumomab_blincyto_all_fn_egr.pdf pcodr_blinatumomab_blincyto_all_in_rec.pdf blinatumomab_blincyto_all_pagfdk.pdf blinatumomab_blincyto_all_fdk_amgen.pdf blinatumomab_blincyto_all_ptfdk_ccsn.pdf blinatumomab_blincyto_all_coi_ccsn.pdf	Acute Lymphoblastic Leukemia	Reimburse with clinical criteria and/or conditions	Complete	Aug 24, 2015	Apr 1, 2016	PC0064-000
Opdivo	Nivolumab	pcodr_provfund_nivolumab_opdivo_metmela.pdf nivolumab_opdivo_mm_fn_rec.pdf nivolumab_opdivo_mm_fn_cgr.pdf nivolumab_opdivo_mm_fn_egr.pdf pcodr_nivolumab_opdivo_metmela_in_rec.pdf nivolumab_opdivo_mm_pagfdk.pdf nivolumab_opdivo_mm_fdk_bms.pdf nivolumab_opdivo_mm_ptfdk_mnc.pdf nivolumab_opdivo_mm_coi_mnc.pdf	Metastatic Melanoma	Reimburse with clinical criteria and/or conditions	Complete	Aug 13, 2015	Apr 1, 2016	PC0063-000
Xgeva	Denosumab (Drug Plan Submission)	cdr_SR0433-001_Xgeva.pdf SR0433-001_complete_Xgeva_OST-Mar-28_16-e.pdf SR0433-001 Xgeva_FWG_OST_PE_Report.pdf SR0433-001 Xgeva_FWG_OST_CL_Report.pdf SR0433-001_Xgeva_PI_Submissions.pdf	Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer	List with clinical criteria and/or conditions	Complete	Jul 31, 2015	Mar 23, 2016	SR0433-001
Strensiq	Asfotase alfa	cdr_SR0443_Strensiq.pdf SR0443_complete_Strensiq-Apr-4-16_e.pdf SR0443 Strensiq _PI_Submissions.pdf SR0443_Strensiq_CL_Report.pdf SR0443_Strensiq_PE_Report.pdf	Hypophosphatasia, pediatric-onset	List with criteria/condition	Complete	Aug 21, 2015	Mar 23, 2016	SR0443-000
Entresto	Sacubitril/valsartan	cdr_SR0447_sacubitril_valsartan.pdf SR0447_complete_Entresto-Mar-22_e.pdf SR0447_Entresto_CL_Report.pdf SR0447_Entresto_PE_Report.pdf SR0447 Entresto Template_PI_Submissions_Consolidated_validated.pdf	Heart failure, NYHA class II or III	List with clinical criteria and/or conditions	Complete	Sep 18, 2015	Mar 18, 2016	SR0447-000
Technivie	Ombitasvir/ paritaprevir/ ritonavir	cdr_SR0444_ombitasvir-paritaprevir-ritonavir.pdf SR0444_cdr_complete_Technivie_March-23-16_e.pdf SR0444_Technivie_CL_Report.pdf SR0444_Technivie_PE_Report.pdf SR0444 Technivie - PI_Submissions_Consolidated_validated.pdf	Hepatitis C, chronic	List with clinical criteria and/or conditions	Complete	Sep 4, 2015	Mar 18, 2016	SR0444-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Drugs for Type 2 Diabetes: Second-Line Therapy Review Update		Feb 7, 2018	Therapeutic Review	Completed	TR0012-000
New Drugs for Type 2 Diabetes: Second-Line Therapy — Recommendations Report		May 23, 2017			TR0012-000
Single Drug Technology Assessment Processes Across Health Technology Assessment Organizations		Dec 9, 2016	Environmental Scan	Completed	ES0293-000
Guidance Document for the Costing of Health Care Resources in the Canadian Setting: Second Edition		Mar 30, 2016			MH0002-CP0009
Drugs for Rare Diseases: Evolving Trends in Regulatory and Health Technology Assessment Perspectives	ES0300_Rare_Disease_Drugs_e.pdf	Feb 11, 2016			ES0300-000
Pruning Emtree: Does Focusing Embase Subject Headings Impact Search Strategy Precision and Sensitivity?	ATS0022_Pruning Emtree_Methods_Project_e.pdf	Apr 16, 2015
Drugs for Pulmonary Arterial Hypertension	TR0006-PAH-InBrief-e.pdf TR0006_PAH_Protocol_e.pdf TR0006_PAH_ScienceReport.pdf TR0006_PAH_Recs_Report.pdf	Mar 16, 2015			TR0006-000
Management of Relapsing-Remitting Multiple Sclerosis	TR0004_RRMS_PiB_e.pdf TR0004-000_RRMS_Protocol_e.pdf TR0004_RRMS_ScienceReport_e.pdf TR0004_RRMS_RecsReport_TR_e.pdf	Nov 29, 2012			TR0004-000
Second and Third-Line Therapy for Patients With Diabetes (Optimal Use Project)	OP0512_Diabetes_Update_PiB_e.pdf OP0512_Diabetes_RecsReport_2nd_3rd-line_e.pdf OP0512_DiabetesUpdate_Second-line_e.pdf OP0512_Diabetes Update_Third-line_e.pdf OP0512_DiabetesUpdate_Incretins-Insulin_e.pdf OU_DiabetesUpdate_Protocol_e.pdf	Dec 29, 2010			OP0512-000
Self-Monitoring of Blood Glucose	C1109_bgts_summary_report_e.pdf C1109-Project-in-Brief-final-e.pdf C1109-Gaps-and-KM-Report-final.pdf compus_BGTS_OT_Rec_e.pdf compus_Current_Practice_Report_Vol-3-Issue-5.pdf compus_CU_Report-BGTS.pdf BGTS_Consolidated_Economic_Report.pdf BGTS_SR_Report_of_Clinical_Outcomes.pdf BGTS_Summary_Protocol_FINAL.pdf	Nov 29, 2010
Portable Monitoring Devices for Diagnosis of Obstructive Sleep Apnea at Home: Review of Accuracy, Cost-Effectiveness, Guidelines, and Coverage in Canada	M0002_Executive Summary_e.pdf M0002_Portable_Monitoring_Devices_Obstructive_Sleep_Apnea_L3_e.pdf	Dec 9, 2009			M0002-000
Development and Testing of Search Filters to Identify Economic Evaluations in MEDLINE and EMBASE	H0490_Executive_Summary_e.pdf H0490_Search_Filters_for_Economic_Evaluations_mg_e.pdf	Oct 30, 2009
English-Language Restriction When Conducting Systematic Review-based Meta-analyses: Systematic Review of Published Studies	H0478_Language_Restriction_Systematic_Review_Pub_Studies_e.pdf	Feb 24, 2009
Emergency department overcrowding in Canada: What are the issues and what can be done?		May 9, 2006

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 600 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Alternative Therapies to Immunoglobulin for Autoimmune Blistering Diseases	Alternative Therapies to Immunoglobulin for Autoimmune Blistering Diseases	May 29, 2023	Health Technology Review	Summary with Critical Appraisal	Completed	RC1483-000
CADTH Pharmaceutical Reviews Update — Issue 37		May 25, 2023	Reimbursement Review	Pharmaceutical Review Update
cemiplimab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	May 25, 2023	Reimbursement Review		Complete	PC0260-000
finerenone	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	May 23, 2023	Reimbursement Review		Complete	SR0737-000
Chloroprocaine for Spinal or Epidural Anesthesia	Chloroprocaine for Spinal or Epidural Anesthesia	May 19, 2023	Health Technology Review	Rapid Review	Completed	RC1482-000
pegcetacoplan	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	May 18, 2023	Reimbursement Review		Complete	SR0748-000
Bevacizumab for Recurrent Platinum-Sensitive Ovarian Cancer	Bevacizumab for Recurrent Platinum-Sensitive Ovarian Cancer	May 17, 2023	Health Technology Review	Rapid Review	Completed	RC1481-000
Overview of HTA Processes for Time-limited Recommendations	Overview of HTA Processes for Time-limited Recommendations	May 16, 2023	Health Technology Review	Environmental Scan	Completed	ES0377-000
Alternative Therapies to Immunoglobulin for Guillain-Barré Syndrome	Alternative Therapies to Immunoglobulin for Guillain-Barré Syndrome	May 15, 2023	Health Technology Review	Rapid Review	Completed	RC1480-000
amivantamab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	May 15, 2023	Reimbursement Review		Complete	PC0289-000
Privately Operated Medical Imaging Facilities Across Canada	Privately Operated Medical Imaging Facilities Across Canada	May 12, 2023	Health Technology Review	CMII Service	Completed	CM0007-000
olaparib	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	May 12, 2023	Reimbursement Review		Complete	PC0299-000
Cognitive Health Assessment Management Platform	Cognitive Health Assessment Management Platform	May 10, 2023	Horizon Scan	Health Technology Update	Completed	EN0046-000
Prostate cancer	Final Report	May 3, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0023-000
durvalumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	May 1, 2023	Reimbursement Review		Complete	PC0296-000
tebentafusp	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	May 1, 2023	Reimbursement Review		Complete	PC0290-000
deferiprone	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 27, 2023	Reimbursement Review		Complete	SR0741-000
berotralstat	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 27, 2023	Reimbursement Review		Complete	SR0723-000
Occupational Therapy for Mental Health Conditions and Substance Use Disorders	RC1478 OT and Mental Health.pdf	Apr 27, 2023	Health Technology Review	Rapid Review	Completed	RC1478-000
Risk of Sexual Transmission of HIV With Antiretroviral Therapy and Variable or Suppressed Viral Load	Risk of Sexual Transmission of HIV With Antiretroviral Therapy and Variable or …	Apr 25, 2023	Health Technology Review	Technology Review	Completed	HC0050-000
pembrolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 25, 2023	Reimbursement Review		Complete	PC0280-000
lumasiran	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Apr 25, 2023	Reimbursement Review		Complete	SR0734-000
anifrolumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 24, 2023	Reimbursement Review		Complete	SR0717-000
Alternative Therapies to Immunoglobulin for Multifocal Motor Neuropathy	Alternative Therapies to Immunoglobulin for Multifocal Motor Neuropathy	Apr 21, 2023	Health Technology Review	Rapid Review	Completed	RC1479-000
Considerations of Access and Inclusion in Adolescent Eating Disorder Care: A Custom Rapid Report	Considerations of Access and Inclusion in Adolescent Eating Disorder Care: A Cu…	Apr 20, 2023	Health Technology Review	Technology Review	Completed	HC0043-000